Boiron SA (EPA:BOI)

Market Cap	343.77M -28.0%
Revenue (ttm)	495.78M -1.8%
Net Income	26.19M +35.2%
EPS	1.51 +35.2%
Shares Out	17.36M
PE Ratio	13.13
Forward PE	n/a
Dividend	1.35 (6.82%)
Ex-Dividend Date	Jun 3, 2026

Volume	5,364
Open	20.00
Previous Close	19.85
Day's Range	19.60 - 20.00
52-Week Range	19.30 - 32.25
Beta	0.21
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 21, 2026

About Boiron

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive l...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 2,623
• Stock Exchange: Euronext Paris
• Ticker Symbol: BOI

Financial Performance

In 2025, Boiron's revenue was 501.11 million, an increase of 2.78% compared to the previous year's 487.56 million. Earnings were 32.64 million, an increase of 187.96%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error